What does this research mean for the field?

Epirubicin provides equivalent therapeutic efficacy to doxorubicin in advanced breast cancer but with significantly reduced cardiac toxicity and fewer gastrointestinal side effects. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

June 1, 1985Journal of Clinical Oncology

A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.

View Full Paper

Ask AI

Bookmark

Why the study?

Does epirubicin reduce cardiotoxicity compared to doxorubicin in patients with advanced breast cancer?

Population

54 patients with advanced breast cancer who had failed prior non-anthracycline combination chemotherapy

Comparison

Epirubicin 85 mg/m2 intravenously every three… vs Doxorubicin 60 mg/m2 intravenously every three…

Design

RCT, randomized

Authors

KJK K JainSanjay Gandhi Post Graduate Institute of Medical Sciences ECE. S. CasperMemorial Sloan Kettering Cancer Center NGNancy L. GellerGeneral Cardiology

Discussion

Member takes

Implication

Supports epirubicin selection to delay cardiotoxicity in advanced breast cancer; confirms equivalent efficacy versus doxorubicin in this RCT.

Structured PICO

Does epirubicin reduce cardiotoxicity compared to doxorubicin in patients with advanced breast cancer?

Population

54 patients with advanced breast cancer who had failed prior non-anthracycline combination chemotherapy

Intervention

Epirubicin 85 mg/m2 intravenously every three weeks

Comparator

Doxorubicin 60 mg/m2 intravenously every three weeks

Outcome

Major therapeutic responses and laboratory evidence of cardiotoxicity (decrease in resting left ventricular ejection fraction of >10% from baseline, or decrease of ≥5% with exercise)safety

Epirubicin demonstrates reduced cardiotoxicity compared to doxorubicin while preserving antineoplastic efficacy in patients with advanced breast cancer.

Cite This Study

Jain et al. (1985) studied this question.

synapsesocial.com/papers/6a1bcd3c6f692abb725ee580 https://doi.org/10.1200/jco.1985.3.6.818

View Full Paper

Ask AI

Bookmark

Implication

Supports epirubicin selection to delay cardiotoxicity in advanced breast cancer; confirms equivalent efficacy versus doxorubicin in this RCT.

A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.

Discussion

Member takes

Implication

Structured PICO

Cite This Study

A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider